In absolute dollar amount, the Cambridge drugmaker had the biggest drop in market cap among any public Massachusetts company ...
With COVID vaccine sales in the doldrums and a respiratory syncytial virus (RSV) vaccine market in “contraction”, Moderna CEO ...
Jim Cramer, host of Mad Money, recently discussed the current state of the market and also discussed both the leading and ...
The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...
Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
(CercleFinance.com) - Moderna a publié sur son site internet une lettre aux actionnaires rédigée par son directeur général, Stéphane Bancel ...
Here are the five things you need to know, including the national day of mourning for Jimmy Carter, California wildfires, Newbury Street rents, and quality goat time ...
Pour 2025, les priorités de Moderna incluent la maximisation de la disponibilité et de la part de marché de ses vaccins ...
The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through ...
In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year ...
so could have "an important role to play in protecting people in the UK from COVID-19 as we enter the winter months," according to Moderna's chief executive Stéphane Bancel. The new version ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback